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Abstract
Background: The etiology of schizophrenia is unknown, but neurodevelopmental disturbances,
myelin- and oligodendrocyte abnormalities and synaptic dysfunction have been suggested as
pathophysiological factors in this severe psychiatric disorder. Cholesterol is an essential
component of myelin and has proved important for synapse formation. Recently, we demonstrated
that the antipsychotic drugs clozapine and haloperidol stimulate lipogenic gene expression in
cultured glioma cells through activation of the sterol regulatory element-binding protein (SREBP)
transcription factors. We here compare the action of chlorpromazine, haloperidol, clozapine,
olanzapine, risperidone and ziprasidone on SREBP activation and SREBP-controlled gene
expression (ACAT2, HMGCR, HMGCS1, FDPS, SC5DL, DHCR7, LDLR, FASN and SCD1) in four CNS-
relevant human cell lines.
Results: There were marked differences in the ability of the antipsychotic drugs to activate the
expression of SREBP target genes, with clozapine and chlorpromazine as the most potent
stimulators in a context of therapeutically relevant concentrations. Glial-like cells (GaMg glioma and
CCF-STTG1 astrocytoma cell lines) displayed more pronounced drug-induced SREBP activation
compared to the response in HCN2 human cortical neurons and SH-SY5Y neuroblastoma cells,
indicating that antipsychotic-induced activation of lipogenesis is most prominent in glial cells.
Conclusion: Our present data show a marked variation in the ability of different antipsychotics to
induce SREBP-controlled transcriptional activation of lipogenesis in cultured human CNS-relevant
cells. We propose that this effect could be relevant for the therapeutic efficacy of some
antipsychotic drugs.
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Background
Schizophrenia is a chronic and serious psychiatric disor-
der affecting about 1 % of the population worldwide. Sev-
eral lines of evidence point towards schizophrenia as a
neurodevelopmental disorder, and the involvement of
myelin- and oligodendrocyte abnormalities in the patho-
physiology of the disease has been suggested [1-5]. Myelin
is formed by oligodendroglial cells and consists mainly of
cholesterol, produced de novo in the CNS [6]. Together,
cholesterol and apolipoprotein E (ApoE) can serve as a
glial growth factor in synaptogenesis [7].
Antipsychotic drugs, such as haloperidol and clozapine,
are used to treat and ameliorate the symptoms of schizo-
phrenia and act, at least in part, by blockage of dopamine
D2-like receptors in the brain. Antipsychotics are usually
classified into two main groups, namely typical (e.g.
haloperidol and chlorpromazine) and atypical drugs (e.g.
clozapine, olanzapine, risperidone and ziprasidone). The
typical antipsychotic drugs are all dopamine D2-receptor
antagonists, whereas the atypical drugs generally have a
more diverse receptor binding profile, suggesting that
other neurotransmitters than dopamine might also be
involved in mediating the antipsychotic effect [8]. Com-
pared to typical antipsychotics, atypical drugs usually
induce less extrapyramidal side effects and may have
improved therapeutic efficacy [9,10]. However, some of
the atypical drugs are associated with side effects such as
weight gain and other metabolic adverse [11].
In a recent study, we demonstrated that haloperidol and
clozapine markedly increase the expression of a cluster of
fatty acid- and cholesterol biosynthetic genes in a human
glioma cell line (GaMg), mediated via activation of the
sterol regulatory element-binding proteins (SREBP) [12].
We proposed that the SREBP-mediated activation of cellu-
lar lipogenesis represents a new mechanism of psycho-
tropic drug action, involved in both therapeutic efficacy
(through enhanced synthesis of cholesterol in CNS) and
the metabolic side-effects (through increased production
of fatty acids and triglycerides in peripheral tissues) [12].
SREBPs are produced as two isoforms; SREBP1 (with two
splice variants, SREBP1a and -1c) and SREBP2. The
SREBP1 and SREBP2 transcription factors are synthesized
as inactive 120 kDa precursors in the endoplasmic reticu-
lum (ER). Upon activation, these proteins are translocated
to the Golgi apparatus by the sterol sensing SREBP-cleav-
age-activating-protein (SCAP) where they undergo prote-
olytical cleavage, releasing a 60–70 kDa fragment that is
transcriptionally active and induces the expression of sev-
eral lipid biosynthetic genes in the nucleus (for review, see
[13]). The different SREBP variants overlap in function to
some extent [14]. In general, SREBP1c controls the expres-
sion of fatty acid biosynthesis genes in various tissues
[15], whereas the SREBP1a isoform is predominant in cell
cultures, activating both cholesterol and fatty acid biosyn-
thesis genes [16,17]. SREBP2 mainly regulates cholesterol
biosynthetic genes both in tissues and in cell culture [18].
In the present study, we have extended our knowledge on
lipogenic effects of psychotropic drugs by comparison of
six antipsychotics with respect to their dose-related ability
to activate SREBP and the expression of SREBP target
genes in human glial GaMg cells. We also examined the
degree of SREBP activation in three additional CNS-
related cell lines, including glial cell lines (astrocytoma
CCF-STTG1 cells) and neuronal cell lines (neuroblastoma
SH-SY5Y cells and cortical neuronal HCN2 cells). We here
report that chlorpromazine, haloperidol, clozapine, olan-
zapine, risperidone and ziprasidone display marked dif-
ferences in their ability to stimulate SREBP-controlled
cellular lipogenesis, and that this effect is most pro-
nounced in glial cells. We propose that SREBP activation
might represent a novel glia-mediated mechanism of
action of some antipsychotic drugs.
Results
Cell viability tests
The effect on GaMg cell viability was investigated for all
six antipsychotic drugs (chlorpromazine, haloperidol,
clozapine, olanzapine, risperiodone and ziprasidone),
using a range of concentrations from 1 μM to 100 μM
(data not shown). Olanzapine had no cell toxic effect at
any of the concentrations tested. Up to 25 μM, no statisti-
cally significant reduction in cell viability was observed
for haloperidol, clozapine and risperidone. Cell viability
in response to chlorpromazine exposure (10 μM and 25
μM) was decreased by about 30 % and 50 %, respectively.
Ziprasidone reduced cell viability by 30 % and 75 % at 10
μM and 25 μM, respectively, as compared to the control.
Antipsychotic-induced activation of the SREBP target 
genes
In an attempt to further understand antipsychotic-
induced stimulation of cellular lipogenesis, we examined
similarities and differences between several SREBP target
genes involved in various aspects of lipid homeostasis. As
shown in Fig. 1a, clozapine (0.1 μM – 50 μM) induced a
statistically significant dose-dependent transcriptional
activation of all nine SREBP target genes examined in cul-
tured GaMg cells. These genes are involved in cholesterol
biosynthesis (ACAT2, HMGCS1, HMGCR, FDPS, SC5DL
and DHCR7; see legend to Fig. 1 for complete names),
cholesterol transport (LDLR) and fatty acid biosynthesis
(FASN and SCD1). The degree of maximum activation
(obtained by 50 μM clozapine) varied markedly between
the different genes, with fold-changes ranging from 2.2
(FDPS) to 7.3 (SCD1) (Fig. 1a). The expression of
SREBP1a and -2 was readily detected, and the expressionBMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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levels of both genes increased markedly with increasing
clozapine concentrations (Fig 1b). The transcriptional
activation was most pronounced for the SREBP2 gene. The
expression of SREBP1c also appeared to be significantly
increased by clozapine (results not shown), but due to the
low expression levels (Ct-values around 36), the interpre-
tation of the data should be cautious.
Comparison of different antipsychotic drugs with respect 
to their SREBP-stimulating effect
In order to compare various drugs with regard to their
ability to activate SREBP-mediated gene expression, a
selection of SREBP target genes (HMGCS1,  HMGCR,
SC5DL and LDLR) was measured after exposing GaMg
cells to various concentrations (0.1, 1, 10 and 25 μM) of
chlorpromazine, haloperidol, clozapine, olanzapine, risp-
eridone or ziprasidone (Table 1). Clozapine and haloperi-
dol, and to a lesser extent olanzapine and
chlorpromazine, clearly enhanced the transcription of all
four SREBP target genes, especially HMGCS1  and
HMGCR. For olanzapine, the stimulating effect was most
pronounced at the highest concentration (25 μM),
whereas chlorpromazine tended to be less effective at the
same concentration, probably due to drug toxicity (see
above). Interestingly, risperidone and ziprazidone dem-
onstrated significantly lower ability to activate the expres-
sion of the SREBP-controlled genes. For ziprasidone, the
limited action could not be overcome by increased con-
centrations, since the drug then induced a marked reduc-
tion in cell viability.
The psychotropic-induced transcriptional activation of
cellular lipogenesis in GaMg cells is due to an increased
proteolytic cleavage of the SREBP transcription factors,
especially SREBP2 [12]. In the present study, we therefore
examined the effect of the six antipsychotics on proteo-
lytic cleavage and activation of SREBP2 only. In western
blot experiments, the semi-quantitative M/P ratio
between the mature transcriptionally active 60–70 kDa
fragment (M) and 120 kDa precursor protein (P) was used
as an indicator of SREBP2 stimulation, as measured after
24 hours of drug exposure in GaMg cells (Fig. 2a). The
degree of SREBP2 activation was parallel to the expression
level of SREBP2 target genes for all drugs (see Table 1 for
comparison). Haloperidol, chlorpromazine, and at higher
non-toxic concentrations, clozapine and olanzapine, all
induced SREBP2 cleavage markedly above the control
level. Risperidone and ziprasidone apparently had less
pronounced or no effect on SREBP2 activation.
Clozapine counteracts the repressive effect of 25-
hydroxycholesterol on SREBP activation
To further explore the mechanism behind the drug-
induced activation of SREBPs, we investigated whether
clozapine could interfere with the effect of 25-hydroxyc-
holesterol (25-HC), a well-known SREBP repressor [19].
The repressive effect of 25-hydroxycholesterol is mediated
by its ability to increase cholesterol transport from the cell
plasma membrane to the SCAP sterol sensor in the ER
[20]. 25-HC (1 μg/ml) markedly reduced basal SREBP2
activity after 2 hours of incubation in cultured GaMg cells
(Fig 2b). Co-treatment with clozapine (30 μM) clearly
counteracted the repressive effect of 25-HC. This opposing
effect was not detectable after longer periods of co-incuba-
tion (4–24 hours), probably due to the high potency of
25HC to repress SREBP (results not shown).
Antipsychotic-induced SREBP activation in the context of 
therapeutic serum concentrations
In clinical practice, the therapeutically relevant serum lev-
els vary considerably between the different antipsychotic
drugs. In order to examine the potential clinical relevance
of the drug-induced SREBP activation that was observed
in cultured cells, the molar concentrations used in the cell
culture experiment were transformed into multiples of the
therapeutically relevant serum concentration for each
drug (Fig 3; see the legend for further details about the
transformation factor). The transformed data illustrate
that although all drugs stimulated HMGCR expression at
some concentrations, only clozapine and chlorpromazine
induced significant SREBP activation in the cell cultures at
concentrations rather close to their therapeutic serum lev-
els. For the other drugs, the stimulation of gene expression
occurred at concentrations far above their therapeutically
relevant serum levels. The issue of cell culture concentra-
tions, serum levels and relevant tissue (brain) concentra-
tions of the drugs is further outlined in the Discussion
section.
Comparison of antipsychotic-induced activation of SREBP 
target genes in different human CNS-relevant cell lines
In order to study whether the antipsychotic-induced
SREBP activation is valid in more than one CNS-related
human cell line, we examined HMGCR  expression in
astrocytoma CCF-STTG1 cells, neuroblastoma SH-5YSY
cells, and cortical neuronal HCN2 cells, all exposed to
clozapine or haloperidol for 24 hours. The largest increase
in gene expression was observed in the astrocytoma cells,
reaching a statistically significant fold change of 5.0 ± 0.2
and 9.4 ± 0.4 with clozapine (25 μM) and haloperidol (25
μM), respectively (Table 2). In contrast, the SH-SY5Y neu-
roblastoma cells displayed minimal activation of the
SREBP transcription system upon drug exposure, with a
relative increase in HMGCR expression of 1.5 ± 0.1 and
1.4 ± 0.1 by haloperidol (25 μM) and clozapine (25 μM),
respectively (Table 2). In the slow growing HCN2 cells,
the  HMGCR  gene expression was activated slightly to
moderately by the drugs, demonstrating that antipsy-
chotic-induced SREBP activation is not a tumor cell-spe-
cific phenomenon. In a pilot experiment (n = 1), we alsoBMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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The effect of clozapine on lipogenic gene expression in GaMg cells Figure 1
The effect of clozapine on lipogenic gene expression in GaMg cells. Gene expression was determined in GaMg cells 
after exposure of various concentrations of clozapine for 24 hours. The level of expression was measured by quantitative RT-
PCR, relative to the expression of the ribosomal gene P0. The p-values were obtained by a Dunnett post-hoc test following a 
one-way ANOVA. Error bars display ± SEM, and the data are representative of three independent parallel experiments. A) 
Relative expression levels of genes involved in cholesterol biosynthesis (filled symbols), cholesterol transport and fatty acid bio-
synthesis (open symbols). The expression of all genes was significantly increased (fold change at 50 μM clozapine, p-value): 
stearoyl-CoA desaturase (delta-9-desaturase; SCD1) (7.4, p = 0.000008), 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(HMGCS1) (5.6, p = 0.000009), fatty acid synthase (FASN) (5.4, p = 0.000008), 7-dehydrocholesterol reductase (DHCR7) (4.3, p 
= 0.000008), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (3.1, p = 0.00001), sterol-C5-desaturase like (SC5DL) (3.1, p 
= 0.00001), acetyl-CoA acetyltransferase 2 (also termed acetoacetyl-CoA thiolase; ACAT2) (3.0, p = 0.00009), low density lipo-
protein receptor (LDLR) (2.8, p = 0.00001) and farnesyl diphosphate synthase (FDPS) (2.8, p = 0.000009). B) Relative expres-
sion levels of SREBP1a (open symbols) and SREBP2 (filled symbols). Both SREBP1a (2.2-fold, p = 0.02) and SREBP2 (2.5-fold, p = 
0.0002) were increased by clozapine in a dose-dependent manner.
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examined the R-Hi-501 rat hippocampus primary cell cul-
ture, which contains both glial and neuronal cells. Incuba-
tion with 25 μM of clozapine led to a 2.1-fold increase in
HMGCR mRNA. The expression levels of HMGCS1 and
FASN were also tested in these cells and increased 1.6- and
2.1 fold, respectively. The basal expression level of
HMGCR was quite similar in all cell types, as measured
with real-time PCR, thereby allowing comparison
between different cell lines with respect to the effect of
drug exposure.
Discussion
In this study, we have extended our initial findings with
haloperidol and clozapine by demonstrating that antipsy-
chotic drugs in general enhance the expression of SREBP-
controlled lipid biosynthetic genes in a concentration-
dependent manner in cultured glial cells, with less pro-
nounced stimulation in neuroblastoma- and cortical neu-
ronal cells. The degree of SREBP activation, however,
varies considerably between the different antipsychotics.
The mechanisms by which the antipsychotic drugs acti-
vate the SREBP system could, in principle, involve recep-
tor-dependent and -independent processes. All
antipsychotic drugs block dopamine D2-like receptors
(DRD2, DRD3 and DRD4), but with marked differences
in their affinities [21,22]. In addition, they also vary
widely in their antagonistic binding to other neurotrans-
mitter receptors, e.g., 5-HT and histamine H1 receptors
[22]. In the present dose-response comparison, haloperi-
dol and clozapine were the most potent activators of
SREBP-controlled gene expression on the basis of their
molar concentrations in the cell cultures, whereas risperi-
done and ziprasidone were minimally effective. Chlorpro-
mazine and olanzapine had intermediate effects. These
data imply that the SREBP activation is neither linked to
the receptor profiles nor the therapeutic classification
(typical vs. atypical) of the drugs, since there is no appar-
ent relationship between these properties and their
SREBP-stimulating effect.
Table 1: Dose response relationships for antipsychotic drug-induced changes in the expression of SREBP target genes
HMGCR HMGCS1 SC5DL LDLR
chlorpromazine
0.1 μM 0.8 ± 0.1 1.0 ± 0.1 1.0 ± 0.09 1.0 ± 0.05
1.0 μM 1.2 ± 0.1 1.8 ± 0.2* 1.2 ± 0.1 1.7 ± 0.3*
10 μM 2.3 ± 0.03*** 3.5 ± 0.3*** 1.4 ± 0.1*** 1.3 ± 0.05*
25 μM 2.6 ± 0.2*** 2.3 ± 0.1** 1.3 ± 0.07** 1.0 ± 0.3
haloperidol
0.1 μM 1.0 ± 0.06 1.1 ± 0.1 1.2 ± 0.02 1.1 ± 0.03
1.0 μM 1.3 ± 0.2 1.7 ± 0.3 1.5 ± 0.1** 1.5 ± 0.1
10 μM 2.7 ± 0.2*** 4.1 ± 0.5** 3.3 ± 0.07*** 2.3 ± 0.2***
25 μM 3.2 ± 0.3*** 3.8 ± 0.8* 3.4 ± 0.2*** 2.8 ± 0.3***
clozapine
0.1 μM 1.1 ± 0.06 1.1 ± 0.03 1.0 ± 0.01 1.1 ± 0.02
1.0 μM 1.2 ± 0.1 1.0 ± 0.01 1.0 ± 0.02 1.2 ± 0.08
10 μM 1.8 ± 0.3* 3.3 ± 0.2*** 1.9 ± 0.1* 1.7 ± 0.2**
25 μM 2.5 ± 0.1*** 5.2 ± 0.6*** 2.8 ± 0.4*** 2.3 ± 0.3***
olanzapine
0.1 μM 0.9 ± 0.03 0.9 ± 0.09 0.8 ± 0.03 1.0 ± 0.1
1.0 μM 1.0 ± 0.1 1.6 ± 0.3 0.9 ± 0.06 1.0 ± 0.05
10 μM 1.2 ± 0.1 1.7 ± 0.2 1.2 ± 0.09 1.3 ± 0.1
25 μM 2.5 ± 0.3* 3.6 ± 0.04*** 1.8 ± 0.3** 2.2 ± 0.3**
risperidone
0.1 μM 0.8 ± 0.05 0.9 ± 0.1 0.8 ± 0.01 0.9 ± 0.05
1.0 μM 0.9 ± 0.1 1.0 ± 0.1 0.9 ± 0.01 1.0 ± 0.08
10 μM 1.2 ± 0.07 1.2 ± 0.05 1.1 ± 0.09 1.2 ± 0.1
25 μM 1.7 ± 0.09** 1.8 ± 0.09 1.6 ± 0.2 1.5 ± 0.07
ziprasidone
0.1 μM 1.1 ± 0.02 1.1 ± 0.05 1.2 ± 0.04 1.1 ± 0.03
1.0 μM 1.1 ± 0.02 1.1 ± 0.1 1.2 ± 0.1 1.1 ± 0.03
10 μM 1.4 ± 0.04* 1.5 ± 0.05* 1.5 ± 0.2 1.3 ± 0.04
25 μM 1.5 ± 0.08* 1.3 ± 0.08* 1.7 ± 0.03** 1.5 ± 0.04
The expression levels of HMGCR, HMGCS1, SC5DL and LDLR were measured by quantitative RT-PCR in cultured GaMg glioma cells, determined 
relative to the expression of the ribosomal gene P0. The fold change is given relative to the vehicle-treated control. The statistical significance was 
denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. The fold changes (mean ± SEM) are representative of three independent parallel 
experiments and measured relative to vehicle treated controlBMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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Proteolytic cleavage of the SREBP2 transcription factor Figure 2
Proteolytic cleavage of the SREBP2 transcription factor. A) The semi-quantitative M/P-ratio of the mature transcrip-
tionally active 60–70 kDa fragment (M) and the SREBP2 120 kDa inactive precursor (P) as a measurement of the degree of 
SREBP2 activation following antipsychotic drug treatment. The results are representative of two independent western blot 
experiments. In agreement with the gene expression results, haloperidol, chlorpromazine, clozapine and olanzapine all induced 
marked SREBP2 cleavage. B) The effect of clozapine on 25-hydroxycholesterol (25-HC) -induced repression of endogenous 
SREBP-2 activity in GaMg cells. Clozapine (30 μM) significantly counteracts the SREBP2 repression induced by 25-HC (1 μg/ml) 
after 2 hours of incubation. The results are representative of two independent experiments.BMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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This assumption is supported by a recent study [23], in
which we demonstrated that several antidepressant drugs
(especially tricyclic antidepressants), but not mood stabi-
lizers (carbamazepine and valproate), activate the SREBP
system in cultured glial cells in a similar manner to the
antipsychotics. This fact makes is likely that the drug-
induced SREBP activation is related to some shared chem-
ical property of these psychotropic compounds. Due to
the different receptor-binding properties of these drugs it
is likely that their shared SREBP-activating effect is medi-
ated via a receptor-independent mechanism of action. All
of the antipsychotics and antidepressants that we have
investigated are cationic amphiphiles. Such substances
have previously been shown to increase the synthesis and
accumulation of total cellular cholesterol levels via a
mechanism involving a reduction of cholesterol levels in
the endoplasmic reticulum (ER), which is the sterol-sens-
ing compartment in the cell [20,24]. SREBP activation is
controlled by the sterol-sensitive SREBP-cleavage-activat-
ing-protein (SCAP) that is located in the ER [25]. When
ER-cholesterol is depleted, SCAP undergoes a conforma-
tional change that promotes translocation of the SREBP/
SCAP complex to the Golgi, representing the inital step in
SREBP activation. Both cholesterol and a hydroxylated
derivative of cholesterol, 25-OH-cholesterol (25-HC),
inhibit the SREBP system by affecting the function of the
SCAP protein [26]. It is therefore interesting to note that
clozapine was able to counteract the SREBP-repressing
effect of 25-HC, which indicates that the effect of antipsy-
chotic drugs on SCAP/SREBP activation is the opposite of
cholesterol and 25-HC. This contrasts in vitro data from a
recent study demonstrating that some cationic
amphiphiles (including clozapine, haloperidol and chlo-
rpromazine) mimic the effect of cholesterol on SCAP con-
formation [27]. However, in line with our results, this
study could not reproduce the cholesterol-mimicking
effect of cationic amphiphiles when tested in cultured
cells [27].
We propose that drug-induced transcriptional activation
of cholesterol biosynthesis in the brain could represent a
new mechanism of action for some psychotropic drugs.
Dose-response curve in antipsychotic-exposed GaMg cells extrapolated to therapeutically relevant serum levels Figure 3
Dose-response curve in antipsychotic-exposed GaMg cells extrapolated to therapeutically relevant serum lev-
els. HMGCR expression levels changes for each drug, following transformation of the molar concentrations used in the cell cul-
ture experiment into multiples of their therapeutically relevant serum levels (see below). Due to effects on cell viability, the 
highest concentrations of chlorpromazine, haloperidol and ziprasidone in the culturing media was 25 μM. Typical and atypical 
antipsychotic drugs are denoted with open and filled symbols, respectively. Note the logarithmic scale on the x-axis. The upper 
therapeutic serum concentration for each drug was set according to the AGNP-TDM expert group consensus guidelines [36]: 
clozapine 2000 nM, chlorpromazine 1000 nM, olanzapine 250 nM, haloperidol 50 nM, risperidone 140 nM and ziprasidone 250 
nM.
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Interestingly, the SREBP-stimulating effect is shared by
several different antipsychotics and antidepressants, dem-
onstrating a common molecular mode of action. This
effect cannot be related to the group-specific antipsy-
chotic- or antidepressant properties of the drugs. Instead,
it might be linked to some common symptoms or deficits
that are present in both schizophrenia and major affective
disorders (e.g., cognitive dysfunctions). This possibility is
further underscored by the therapeutic breadth of these
classes of drugs, with antipsychotic drugs frequently used
in treatment of depressed patients and vice versa.
Involvement of myelin- and oligodendrocyte (glial)
abnormalities has been indicated in the etiology of both
schizophrenia and bipolar disorder [1-5]. The myelina-
tion process requires intact cholesterol biosynthesis
[6,28], and during CNS development, the expression of
cholesterol biosynthesis genes is enhanced [29]. Further-
more, malfunction of synaptic processes, including
reduced dendritic spine density, has been proposed in the
pathophysiology of schizophrenia [30-33]. Cholesterol,
together with ApoE, can act as a glia-derived growth factor
supporting the formation of synapses in culture [7]. In
line with this, cholesterol has recently been demonstrated
as essential for dendrite maturation, the rate-limiting step
in glia-induced synaptogenesis, and is required for contin-
uous synapse development in cultures [34]. Interestingly,
drug-induced SREBP activation was most evident in the
glial-like GaMg glioma- and CCF-STTG1 astrocytoma cell
lines, and less pronounced in the HCN2 cortical neuron
cells and in a primary cell culture from rat hippocampus.
Lipogenic activation was almost absent in SH-SY5Y neu-
roblastoma cells. These data are in agreement with the fact
that in the CNS, the majority of cholesterol is produced de
novo by glial cells [6]. Cultured neurons have a poorly
developed machinery for cholesterol biosynthesis and
rely on glia-derived cholesterol for synaptogenesis [35]. It
is thus conceivable that drug-induced SREBP-controlled
activation of glial cholesterol biosynthesis in the brain
represents a receptor-independent therapeutic mecha-
nism of action and provides essential building blocks to
the myelination process or synaptogenesis.
A critical issue is whether the SREBP-stimulating effect
observed in cultured cells also occurs during drug treat-
ment in the clinical setting. Although any interpretation
of the clinical relevance of cell culture data is difficult, the
relationship between in vitro and in vivo (therapeutically
relevant) concentrations of the drugs requires special
attention. The investigated drugs are clinically efficacious
at highly different ranges of serum concentrations [36]. In
an attempt to highlight the possible clinical impact of
their SREBP-activation, we transformed the molar concen-
trations of each drug (as used in the GaMg cell culture
experiments) into multiples of the therapeutically rele-
vant upper serum concentrations of the corresponding
drug (as determined from the AGNP-TDM expert group
consensus guidelines) [36]. By this approach, clozapine
and chlorpromazine appeared to significantly activate the
SREBP system in the cultured cells at concentrations that
were 5–10-fold above their therapeutic serum levels. In
contrast, the concentration of haloperidol necessary to
induce this lipogenic effect in the cultured cells was about
200 times higher than the clinically relevant serum level,
and ziprasidone hardly activated the SREBP pathway at
all. It is important to bear in mind that many psychotropic
drugs are highly lipophilic, leading to enrichment in lipid-
rich tissues. Levels of haloperidol and clozapine have
been demonstrated to be 10–30 times higher in the CNS
compared to the corresponding serum concentration
[37,38]. Taken together, these data indicate that SREBP-
activation by clozapine and chlorpromazine might occur
in the brain when serum levels are within their therapeu-
tically relevant range, whereas the SREBP activation
observed for haloperidol would be expected to be of
minor clinical relevance. Interestingly, clozapine has been
Table 2: HMGCR gene expression changes in human astrocytoma and neuroblastoma cell lines
Haloperidol Clozapine
Cell type 10 μM2 5   μM1 0   μM2 5   μM
SH-SY5Y 1.3 ± 0.06* 1.5 ± 0.1* 0.9 ± 0.02 1.4 ± 0.1*
CCF-STTG1 5.3 ± 0.6** 9.3 ± 0.4*** 1.5 ± 0.2* 5.0 ± 0.2***
HCN2 1.2 ± 0.03* ND ND 2.4 ± 0.2 **
Human CCF-STTG1 astrocytoma and SH-SY5Y neuroblastoma cells were exposed to haloperidol and clozapine (10 μM and 25 μM of each drug), 
and human cortical neuron HCN2 cells were exposed to haloperidol (10 μM) and clozapine (25 μM). The HMGCR-expression was determined 
relative to the expression of P0 in all cell lines. For CFF-STTG1 and SH-SY5Y, statistical significance of drug-induced HMGCR expression was 
determined by the Dunnetts post-hoc test that correct for multiple testing, as described in Materials and methods. For the HCN2-cells that had 
only two comparisons, the student's t-test was applied. Each statistical comparison was performed between drug treated cells and vehicle treated 
control. Significance was denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. The fold changes (mean ± SEM) are representative of three 
independent parallel experiments and measured relative to vehicle treated control. ND: Not determined.BMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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described as a drug with superior therapeutic efficacy
[39,40], with positive effects in otherwise treatment-
refractory patients. However, a similar supremacy has not
been shown for chlorpromazine, the other apparent
potent SREBP-activating drug. Finally, it is uncertain how
large an in vivo response would need to be in order to be
of any clinical relevance, since even minor changes in cel-
lular lipid biosynthesis in vivo could have marked clinical
effects. Caution should always be taken when making
inferences from cell cultures to the clinical setting, and
further studies are indeed warranted to draw more reliable
conclusions about the clinical impact of our results.
Conclusion
We here extend our initial studies with haloperidol and
clozapine by demonstrating that antipsychotic drugs in
general stimulate SREBP-controlled gene expression in
several CNS-relevant cell lines, but with marked differ-
ences between the various drugs and types of cells. We
have previously suggested that the psychotropic-induced
SREBP activation is a glial-mediated mechanism of drug
action. This proposal is supported by our present results,
demonstrating that the lipogenic effect is apparently more
pronounced in glial than in neuronal cell lines. We
hypothesize that drug-induced transcriptional activation
of cholesterol biosynthesis in the brain represents a recep-
tor-independent mechanism of therapeutic action of
some antipsychotic drugs, possibly by providing essential
building blocks for the myelination process and synap-
togenesis. Further studies on gene expression changes and
lipid parameters in blood samples from drug-treated
patients and brain tissue from animal models should be
undertaken.
Methods
Cell cultures
The human glioma GaMg cell line was kindly provided by
an in-house source [41]. The R-Hi-501 rat hippocampal
primary cell culture was purchased from Cambrex (Cam-
brex Biosciences, USA). All other cell lines were purchased
from ATCC (LGC Promochem, UK). GaMg human gliob-
lastoma cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM) containing 2 mM L-glutamine, 4.5 g/L
glucose and 10 % fetal bovine serum (FBS). CCF-STTG1
human astrocytoma cells were grown in RPMI 1640
medium containing 2 mM L-glutamine 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM
sodium pyruvate and 10 % FBS. SH-SY5Y human neurob-
lastoma cells were cultured in Eagle's Minimum Essential
Medium (EMEM) containing 1.5 g/L sodium bicarbonate,
1.0 mM sodium pyruvate, 0.1 mM non-essential amino
acids (NEAA), 2 mM L-glutamine and 10 % FBS. HCN2
human cortical neuron cells cells (derived from cortical
tissue removed from a patient undergoing hemispherec-
tomy for intractable seizures associated with Rasmussen's
encephalitis) were grown in DMEM medium containing
1.5 g/L sodium-bicarbonate, 4.5 g/L glucose and 4 mM L-
glutamine and 10 % FBS. R-Hi-501 rat hippocampal cells
were grown in Neurobasal Medium containing 2 mM L-
Glutamine and 2 % B27 supplement. GaMg, CCF-STTG1
and SH-SY5Y cells were cultured on 6-well plates (TPP,
Switzerland) in monolayer to high confluence. HCN2
were cultured on laminin/poly-D-lysine coated 6-well
plates (Becton Dickinson, USA) at high confluence. R-Hi-
501 cells were grown in poly-D-lysine and laminin coated
plates, prepared according to the manufacturers recom-
mendations. All cells were incubated in the presence of
100 U/ml Penicillin-Streptomycin Mixture (Cambrex Bio-
sciences) in 5 % CO2 at 37°C. The cell lines were cultured
for 1–2 days before drug exposure and experiments were
performed in triplicate, with the exception of the R-Hi-
501 cells (n = 1).
Drug exposure and cell viability testing
For examination of the effects on cell viability for
haloperidol (Janssen-Cilag, Belgium), chlorpromazine
(Sigma-Aldrich, USA), clozapine (Sigma-Aldrich), olanza-
pine (Toronto Research Chemicals, Canada), risperidone
(Sigma-Aldrich) and ziprasidone (Toronto Research
Chemicals), we used the Cell Proliferation Reagent WST-
1 (Roche Diagnostics, Germany). GaMg cells were spread
out with a density of 6000 cells/well (96 multi-well
plates) and exposed to 1, 5, 10, 25, 50 and 100 μM of the
respective drug for 24 hours. Cell viability in response to
drug exposure was compared to the growth of vehicle-
exposed (lactic acid, 6 μg/ml) cells as well as to a cell den-
sity gradient created by plating out 3000, 4000, 6000,
8000 or 10000 GaMg cells per well. The WST-1 analysis
was performed in accordance with the supplier's recom-
mendations. All experiments were initiated by replace-
ment of the pre-exposure media with fresh media
containing vehicle control (lactate acid) or the respective
drug. All experiments were performed in quadruplicate.
RNA extraction, cDNA synthesis and real-time PCR 
analysis
After drug exposure, cells were trypsinated and total RNA
was extracted using the ABI PRISM™ 6100 Nucleic Acid
PrepStation (Applied Biosystems, USA). RNA quantity
and quality was measured on the NanoDrop® ND-1000
spectrophotometer (NanoDrop Technologies, USA).
cDNA was synthesized using the TaqMan Reverse Tran-
scription (RT) reagents (Applied Biosystems) and used as
template for real-time PCR analysis on an ABI Prism
7900HT sequence detector system (Applied Biosystems)
with SYBR-green (Eurogentec, Belgium) as detector, as
previously described [12]. Each sample was run in tripli-
cate. The relative gene expression levels were determined
with the comparative ΔCt-method [42] and normalized
relative to the ribosomal protein P0 gene. Similar resultsBMC Neuroscience 2006, 7:69 http://www.biomedcentral.com/1471-2202/7/69
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were obtained in a pilot study when normalizing relative
to GAPDH and B-actin.
Immunoblot analysis
GaMg cells were seeded into 6-well plates and left to
adhere over night. To reduce the endogenous SREBP activ-
ity, the medium was supplemented to contain 20 % FBS
three hours prior to addition of the drugs or vehicle. The
cells were grown in the same medium for 24 hours during
drug exposure. In order to terminate the experiments, cell
cultures were washed twice with cold PBS before adding
RIPA lysis buffer (15 mM NaCl, 50 mM TRIS, 0.5 %
sodium deoxycholate, 1 % Np-40 and 0.1 % SDS) con-
taining Complete protease inhibitor (one tablet per 10 ml
RIPA; Roche Diagnostics, USA). To achieve complete lysis,
the cell suspensions were kept in the RIPA-containing
buffer for 30 min at 4°C, before storage at -20°C.
For Western blotting, the samples were thawed and centri-
fuged in an Eppendorf 5415D microcentrifuge (Eppen-
dorf, USA) at 16000 × g for 10 minutes. Protein content
was determined from the supernatant using the Bio-Rad
DC (detergent compatible) Protein Assay (Bio-Rad Labo-
ratories, USA). Immunoblotting was performed by the
Western Breeze system (Invitrogen, USA): 10 μg of total
protein from each sample was separated on NuPAGE 4–
12 % Bis-Tris Gels and blotted onto Invitrolon™ PVDF
membranes. The membranes were incubated overnight at
4°C with 1.5 μg/ml purified monoclonal anti-human
SREBP2 mouse antibody (IgG-1C6, BD Biosciences
Pharmingen, USA), and probed with alkaline phos-
phatase-conjugated goat anti-mouse secondary antibody
solution (Invitrogen) for 1 hour. Chemiluminescence
detection was performed according to manufacturer's
instructions (Invitrogen). The SREBP2 activation was
semi-quantified as the signal intensity of the mature (M)
active 60–70 kDa SREBP fragment divided by the signal
intensity of the inactive 120 kDa precursor (P) protein,
annotated as the "M/P-ratio". Signal intensity measure-
ments were performed with computer-assisted densitom-
etry and image scanning using the Fuji Las-1000
luminescent image analyzer (Fuji, Japan) and the Image
Gauge v4.0 software (Fuji).
Statistical analysis
Relative gene expression values were analyzed by one-way
analysis of variance (ANOVA), when not stated otherwise.
When the ANOVA test indicated statistical significance, a
Dunnett post-hoc test was applied to determine the con-
centrations where the change in gene expression was sta-
tistically different from the vehicle-treated control. In
experimental setups with only few comparisons, the stu-
dent's t-test was applied. All statistical tests were con-
ducted with Statistica®  software version 6.0 (StatSoft,
USA).
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